Reviews
Towards the identification of novel autoantibodies in Sjögren's syndrome
T. Witte1, F. Engelke2, J. Ritter3, T. Dörner4, S. De Vita5, A.V. Goules6, A.G. Tzioufas7
- Klinik für Rheumatologie und Immunologie, Medical School Hannover, Germany. witte.torsten@mh-hannover.de
- Klinik für Rheumatologie und Immunologie, Medical School Hannover, Germany.
- Department of Medicine and Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, and German Rheumatism Research Centre (DRFZ), Berlin, Germany.
- Department of Medicine and Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, and German Rheumatism Research Centre (DRFZ), Berlin, Germany.
- Clinica di Reumatologia, DPMSC, Azienda Ospedaliero-Universitaria S. Maria della Misericordia, Udine, Italy.
- Department of Pathophysiology, School of Medicine, National University of Athens, Greece.
- Department of Pathophysiology, School of Medicine, National University of Athens, Greece.
CER15904
2022 Vol.40, N°12
PI 2395, PF 2397
Reviews
Free to view
(click on article PDF icon to read the article)
PMID: 36226613 [PubMed]
Received: 29/05/2022
Accepted : 11/07/2022
In Press: 12/10/2022
Published: 20/12/2022
Abstract
Primary Sjögren’s syndrome may be difficult to diagnose when antibodies against Ro/SSA are lacking, and can be grouped in at least four clusters indicating different pathophysiological pathways. Novel biomarkers, in particular autoantibodies, would be helpful in diagnosing Sjögren’s syndrome and in further identification and characterisation of the clusters. In this review, we describe new technologies that may be utilised in the rapid identification of novel autoantibodies, and an example of how well characterised patients, here from the HarmonicSS cohort, are a prerequisite in the discovery of clinically meaningful biomarkers. This translational approach hold promise to optimise the diagnosis and treatment of individual pSS patient subsets.
